CAF protocol

1.	Breast Neoplasms (Breast Cancer) 10/01/1999 - "Patients with poor-prognosis stage IV breast cancer were treated with this "neo-FAC" as front-line therapy. " 03/01/2001 - "A total of 121 patients with small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and breast cancer (BC) were randomized into carboplatin injection group (study group) and carboplatin powder group (control group), treated with CE, CIE and CAF protocol, respectively. " 10/01/1999 - "'Neo-FAC' (5-fluorouracil, doxorubicin, and cyclophosphamide) for poor-prognosis stage IV breast cancer: a Southwest Oncology Group Phase II Study." 10/01/1998 - "Considering the recommended dose of the docetaxel/doxorubicin combination (75 mg/m2 and 50 mg/m2, respectively), we decided to proceed with a pilot program in untreated metastatic breast cancer aimed at defining a multidrug regimen that could be later randomly compared with a standard doxorubicin-containing polychemotherapy regimen with equidoses of doxorubicin such as the FAC protocol (5-fluorouracil 500 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2) in first-line metastatic and adjuvant treatment of breast cancer patients. " 01/01/1990 - "We have observed the type and intensity of side effects of cytostatic therapy suffered by patients with breast cancer during postoperative period (after radical mastectomy) 28 patients have been treated by CMF protocol (cyclophosphamide, methotrexate, 5-fluorouracil) 29 patients by FAC protocol (5-fluorouracil, adriamycin cyclophosphamide) 31 patients by Cooper protocol (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednizon). " Order ALL the reference details at left...
2.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/01/2001 - "A total of 121 patients with small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and breast cancer (BC) were randomized into carboplatin injection group (study group) and carboplatin powder group (control group), treated with CE, CIE and CAF protocol, respectively. " Order ALL the reference details at left...
3.	Anticipatory Vomiting 09/01/1996 - "For at least one cycle of chemotherapy 86.1% and 91.7% patients in the FAC protocol presented vomiting and nausea respectively: 11.1% had anticipatory vomiting and 30.6% had anticipatory nausea. " Order ALL the reference details at left...
4.	Vomiting 09/01/1996 - "For at least one cycle of chemotherapy 86.1% and 91.7% patients in the FAC protocol presented vomiting and nausea respectively: 11.1% had anticipatory vomiting and 30.6% had anticipatory nausea. " Order ALL the reference details at left...
5.	Nausea 09/01/1996 - "For at least one cycle of chemotherapy 86.1% and 91.7% patients in the FAC protocol presented vomiting and nausea respectively: 11.1% had anticipatory vomiting and 30.6% had anticipatory nausea. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Fluorouracil (Carac)
2.	Doxorubicin (Adriamycin)
3.	Cyclophosphamide (Cytoxan)
4.	Carboplatin (JM8)
5.	Vincristine (Oncovin)
6.	Methotrexate (Mexate)
7.	docetaxel (Taxotere)
8.	CMF protocol

Related Therapies and Procedures

1.	Radical Mastectomy
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Drug Therapy (Chemotherapy)

Best Treatments:
Research Summary Report
on Breast Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3868 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>